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Kasper Linde Ankjærgaard1*, Philip Tønnesen2, Lars Christian Laursen3, Ejvind Frausing Hansen4,
Helle Frost Andreassen5 and Jon Torgny Wilcke1Abstract
Background: In chronic obstructive pulmonary disease, the prognosis for patients who have survived an episode of
acute hypercapnic respiratory failure due to an exacerbation is poor. Despite being shown to improve survival and
quality-of-life in stable patients with chronic hypercapnic respiratory failure, long-term noninvasive ventilation is
controversial in unstable patients with frequent exacerbations, complicated by acute hypercapnic respiratory failure.
In an uncontrolled group of patients with previous episodes of acute hypercapnic respiratory failure, treated with
noninvasive ventilation, we have been able to reduce mortality and the number of repeat respiratory failure and
readmissions by continuing the acute noninvasive ventilatory therapy as a long-term therapy.
Methods: Multi-center open label randomized controlled trial of 150 patients having survived an admission with
noninvasive ventilatory treatment of acute hypercapnic respiratory failure due chronic obstructive pulmonary
disease. The included patients are randomized to usual care or to continuing the acute noninvasive ventilation as a
long-term therapy, both with a one-year follow-up period. The primary endpoint is time to death or repeat acute
hypercapnic respiratory failure; secondary endpoints are one-year mortality, number of readmissions and repeat
acute hypercapnic respiratory failure, exacerbations, dyspnea, quality of life, sleep quality, lung function, and arterial gases.
Discussion: Though previous studies of long-term noninvasive ventilation have shown conflicting results, we believe
the treatment can reduce mortality and readmissions when applied in patients with previous need of acute ventilatory
support, regardless of persistent hypercapnia.
Trial registration: clinicaltrials.org: NCT01513655 16-Jan-2012.
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Randomized controlled trialBackground
Noninvasive ventilation (NIV) has been shown to improve
survival in patients with chronic obstructive pulmonary
disease (COPD), admitted with acute hypercapnic respira-
tory failure (AHRF) [1]; and NIV is recommended as a
treatment of AHRF due to COPD [2]. COPD patients hav-
ing survived AHRF have a poor prognosis; Chu et al. have* Correspondence: ankjaergaard@live.dk
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life-threatening event (death or repeat AHRF) of 63.3 %;
and of death of 49.1 % [3].
Hypothetically, long-term NIV (LTNIV) can improve
the prognosis for severe COPD. The majority of trials
have focused on patients with chronic hypercapnic re-
spiratory failure due to stable COPD (i.e., patients with
no exacerbations prior to LTNIV initiation); and their
results have been conflicting [4]. However, in 2014,
Köhnlein et al. published the results of a large random-
ized controlled trial (RCT) of LTNIV for stable patientsarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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[5]: The patients treated with LTNIV had a one-year
mortality of 12 % vs. 33 % for the controls; and the pa-
tients treated with LTNIV scored higher in health-
related quality-of-life (HRQoL).
Three RCTs have studied the effects of LTNIV for un-
stable COPD, i.e., where the participants were enrolled
after an admission with NIV treatment of AHRF:
Cheung et al. and found that the patients treated with
LTNIV had a lower rate of repeat AHRF (38.5 %/year vs.
60.2 %/year, p = 0.039) [6]; and Funk et al. found that the
LTNIV group had a longer mean time to clinical worsen-
ing (391 days vs. 162 days; p = 0.0018) [7]. However, the
largest RCT by Struik et al., showed no differences
between the LTNIV group and the controls [8].
Little is known of what predicts AHRF in severe COPD.
However, based on the large ECLIPSE study on exacerba-
tions of COPD, Hurst et al. [9] and Müllerova et al. [10]
showed that previous exacerbations predict new exacerba-
tions [9]; and that previous admissions due to exacerba-
tions of COPD predict new admissions and death [10].
We assume that previous admissions with AHRF due
to COPD could predict new admissions with AHRF and
need of NIV, as well as death.
We retrospectively analyzed 20 patients who were treated
with LTNIV and followed at our pulmonary ward. The pa-
tients were offered LTNIV if they had been admitted for
NIV treatment of AHRF at least twice. We found that the
patients’ number of AHRF episodes and admissions due to
COPD decreased significantly. And only four of the patients
(20 %)—considerably less than the 49.1 % showed by Chu
et al.—died within one year after initiation. Furthermore,
these highly selected patients tolerated LTNIV well.
Aim
The aim of this RCT is to investigate whether LTNIV
can reduce mortality or repeat AHRF in patients who
have been admitted for NIV treatment of AHRF due to
COPD; and, secondarily, whether LTNIV can reduce
mortality per se and the number of repeat AHRF, read-
missions, and exacerbations, and improve quality of life.
Methods/Design
COPD patients who are admitted for NIV treatment of
AHRF (pH < 7.35 and Pa,CO2 > 6 kPa) at Gentofte,
Bispebjerg, Hvidovre or Herlev Hospitals in Greater
Copenhagen are eligible. The patients must be optimally
treated according to GOLD guidelines [2]. The patients
must reside in the Capital Region, be able to give a
verbal consent and sign a written consent form, and
understand Danish.
The patients are excluded if they cannot comply with
NIV or have a respiratory rate <12/min, severe hypoxia
requiring more than 15 L O2/min, or a high risk ofaspiration, recent abdominal, facial or upper airway sur-
gery, malignancy or life expectancy of less than 6 months
because of diseases other than COPD, known obstruct-
ive sleep apnea syndrome (OSAS), or a StHCO3
− less
than 20 mmol/L.
Design
The study is a multi-center randomized, controlled, open-
label study. The participants are included during an ad-
mission with NIV treatment of AHRF due to COPD. If
the patient gives consent (see below), he or she is random-
ized to either LTNIV or usual care. The acute NIV therapy
is continued for as long the patient presents a hypercapnic
acidosis or severe dyspnea without NIV; hereafter, NIV is
ceased in the patients in the control group, whereas it is
continued with the same settings in the LTNIV patients.
When stable and when deemed appropriate by a phys-
ician, the patients are discharged.
The included patients will be given the possibility of
contacting an acute hotline, operated by a nurse.
One week after discharge, all patients are visited by a
nurse. The patients are followed in the outpatient de-
partments with visits 1, 3, 6, 9, and 12 months after
discharge.
A participant who is readmitted will not be re-
randomized. If the participant is in the intervention
group, LTNIV is resumed, if paused.
Consent
When stabilized and able to have a small pause from
NIV, the patient is presented to the study. If inter-
ested, the patient is formally informed of the study by
one of the attending physicians. This is typically
2 days after admission, although individual. The infor-
mation session is held with a physician who has de-
voted time for this and who is not disturbed. When
informed, the consent form is signed by the patient
and the informing physician. If the participant wants
time for consideration, a new session will be planned
one or two days later.
No individual data will be published.
Intervention
For the intervention group, the acute NIV treatment is
continued as LTNIV with the pressures and settings
which had reversed the respiratory failure and the hyper-
capnic acidosis. The participant is offered to initiate an
average volume-assured pressure support, but this is not
mandatory.
Before discharge, the participant and caregivers are
trained in handling and cleaning the ventilator, tubes,
masks, etc. The participant is told to use the ventilator
for a minimum of six hours of daily, preferably during
sleep.
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LTNIV is optimized according to the participant’s re-
quests or complaints.
One month after discharge, LTNIV participants who
have had only this one episode of AHRF and who do not
feel a subjective improvement are offered to pause the
LTNIV therapy, provided they have not had any of the
following after discharge: exacerbation; need for antibi-
otics, increased oral corticosteroids, or inhaled medicine;
hospitalization or visit to an emergency room or emer-
gency physician due to COPD; fever of 38 °C or higher
for at least one day; increased or purulent expectoration;
or increasing dyspnea for at least one day.
If it is agreed to pause LTNIV, the participant is
instructed to resume LTNIV at one or more of the above
symptoms.
Randomization
A total of 150 COPD patients will be included from the
four wards. The participants are randomized to LTNIV
or usual care in a 1:1 ratio, using a computer-generated
block-randomization for each center. The participant is
presented with a sealed envelope containing a piece of
paper with either “A” (= LTNIV) or “B” (= usual care).
The randomization list is stored at Gentofte Hospital in
a sealed envelope. 50 sealed envelopes are prepared for
each center.
Outcomes
Primary outcome is difference in time to death or repeat
AHRF between the study’s two groups. AHRF is defined
as a pH < 7.35 and a Pa,CO2 > 6 kPa despite optimal treat-
ment according to GOLD guidelines, i.e., nebulized
bronchodilators and intravenous corticosteroids [2].
The secondary outcomes are differences in the follow-
ing variables; one-year mortality, admissions due to
COPD; admissions due to repeat AHRF; visits to the
emergency department or to an emergency physician
due to COPD; exacerbations treated with oral corticoste-
roids or oral antibiotics; body mass index; forced expira-
tory volume in one second (FEV1); cost efficiency;
health-related quality-of-life (HRQoL), measured by
COPD Assessment Test (CAT) and Severe Respiratory
Insufficience Questionnaire (SRI); sleep quality, mea-
sured by the Epworth Sleepiness Scale (ESS); apnea/
hypopnea index (AHI); and Medical Research Council's
Dyspnea scale (MRCD).
Sample size/power calculation
Chu et al. showed that the one-year risk of death or
repeat AHRF for COPD patients having survived an
admission with NIV treatment of AHRF is 63.3 % [3];
and, for the LTNIV group in the RCT by Cheung et al.,
this risk was 38.5 % [6].We use these risks for the power calculation. We
accept a 0.05 risk of type 1 error (α) and 0.2 of type 2
error (β). With a power of 0.8, the needed sample size is
120. With an expected dropout of 20 %, we intend to
include 150 participants, 75 in each arm.Measurements
Upon admission, we measure: arterial blood gases with
Pa,CO2, Pa,O2, pH and StHCO3
−, firstly to diagnose the
AHRF and secondly, in order to titrate the NIV treat-
ment; regular, venous blood samples, analyzing infec-
tious parameters, red and white blood count, kidney-
and liver parameters; electrocardiogram (ECG); and a
chest x-ray.
These measurements are done as a standard at the
acute admission and not as part of the protocol.
At discharge, we measure: lung function, i.e., FEV1,
FVC and FIVC; peripheral oxygen saturation (SpO2%); ar-
terial blood gases with Pa,CO2, Pa,O2, pH and StHCO3
−;
height and weight; MRC Dyspnea score; CAT, SRI and
ESS questionnaires; and we note status of medication
and long-term oxygen treatment (LTOT), when relevant.
For the intervention group, we read ventilator’s SIM
card in regard to compliance, daily use, and apnea-
hypopnea index (AHI).
At the home visit one week after discharge, we meas-
ure: lung function and SpO2%.
For the intervention group, we ensure that the ventila-
tor, the mask and the hose are well-functioning; and that
the patient is well informed and uses the ventilator
correctly.
At the outpatient visits, we measure: lung function;
SpO2%; arterial blood gases; weight; exhaled concentra-
tion of carbon mono-oxide; MRCD; CAT, SRI and ESS
questionnaires; and we note status of medication, smok-
ing, and LTOT, when relevant.
For the intervention group, we read ventilator’s SIM
card in regard to compliance, daily use, and AHI.
At each outpatient visit and at the end of the pa-
tient’s study period, we collect data on mortality, hos-
pital admissions, exacerbations treated by a general
practitioner or an emergency physician, and emer-
gency room visits.Collecting of data
All participants have an individual case report file (CRF)
in which all data will be noted. The CRF contains nine
sections; a front page with the basic information on the
participant, i.e., the patient number, date of consent,
allocation, ventilator settings (if relevant) etc.; and a
section for each event in the study, i.e., admission, dis-
charge, home visit, and the five outpatient visits includ-
ing completion data in the fifth.
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tion. The files are stored in a locked room to which only
the investigators have access.
Data processing
The primary outcome is the difference in time to death
or AHRF between the LTNIV group and the control
group, analyzed as an Intention-To-Treat analysis and
calculated in a Cox proportional hazards regression,
using Kaplan-Meier and log rank.
The differences between the study’s two groups will be
computed using X2-statistics for the dichotomous vari-
ables and t-tests for the continuous variables, assuming
that data will follow a normal distribution. Differences in
time to a given event are calculated in a Cox propor-
tional hazards regression, using Kaplan-Meier survival
statistics and log rank.
For all comparisons, p < 0.05 is the level of
significance.
For the sample size calculation, we used SAS (Statistical
Analysis System, version 9.4).
We will use the latest versions of SAS for the statis-
tical analyses.
Publications
Both positive and negative results will be published in
national and international journals and at conferences,
symposia, etc.
Ethics
The study was approved by the Regional Committee on
Health Research Ethics (DNVK) of The Capital Region,
Data Protection, and Drug Authority. Trial no. H-1-
2011-084.
The trial is conducted at four different geographical
locations:
1) Dept. of Pulmonary Medicine Y, UH Gentofte,
Hellerup, Denmark, DK-2900
2) Dept. of Internal Medicine O, UH Herlev, Herlev,
Denmark, DK-2730
3) Dept. of Pulmonary Medicine and Cardiology, UH
Hvidovre, Hvidovre, Denmark, DK-2650
4) Dept. of Pulmonary Medicine, L, UH Bispebjerg,
København NV, Denmark, DK-2400
The four hospitals are all governed by the Capital
Region of Denmark; thus, administratively and legally,
the four hospitals are one. Therefore, by Danish law,
only one ethics committee approvalwas needed.
Trial registration:
The trial was registered at clinicaltrials.org. Registration
number: NCT01513655, 16-Jan-2012.No individual or personally identifiable data will be
published.
Biological material
The only biological samples taken are general blood
biochemistry and arterial blood gases. This is the
standard for any admission and outpatient visit. The
samples are handled by the Dept. of Clinical Biochem-
istry according to current guidelines; after analysis, the
samples are destroyed. No biological material is stored.
Arterial blood gas samples measure approximately
1 mL; venous blood samples measure approximately
10–15 mL.
Discussion
This RCT will assess whether LTNIV can reduce mortal-
ity and prevent exacerbations and repeat AHRF in un-
stable COPD patients having survived an admission due
to AHRF. Three previous RCTs have assessed LTNIV for
COPD patients after an episode of AHRF, treated with
NIV; the results have been conflicting as the two smaller
RCTs showed that LTNIV could reduce repeat AHRF
and clinical worsening [6, 7], whereas the largest RCT
showed no effect [8].
In the large RCT and in one of the two small, an add-
itional inclusion criterion was persistent hypercapnia
without acidosis after the AHRF episode [7, 8].
It is documented that previous exacerbations of COPD
predict new exacerbations [9] and that previous admis-
sions due to exacerbations predict new admissions and
death [10].
Based on this and on our experience with LTNIV
for COPD, we believe that LTNIV can reduce mortal-
ity and repeat AHRF, regardless of whether the pa-
tient was persistently hypercapnic after the acute NIV
treatment. We are looking forward to assessing this
in an RCT.
Blinding
The study is randomized with an intervention group and
a control group. The random sequence generation is
random and unknown to the investigators. However, the
study is open label, i.e., unblinded; the patient allocation
cannot be concealed, as the patients will necessarily
know whether they receive LTNIV or usual care. We
considered the possibility of using sham NIV or CPAP
in the control group; but we assume it would not be
worthwhile, as the patients would undoubtedly figure
out their allocation. Furthermore, CPAP could affect
quality-of-life negatively and thus favor the NIV treat-
ment group. We believe that—by offering the same out-
patient monitoring in the two arms, and as our primary
outcome is mortality—the risk of bias in an open trial
will be minimal.
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There are few side effects of NIV treatment:
Some people feel uncomfortable wearing the mask, as
it fits tightly to the face; some will experience dryness of
the eyes, nose and mouth, due to the airflow. The mask
can—if not fitted and placed properly—give pressure ul-
cers, especially over the nose. Due the high ventilator
pressures, the user can get a sense of flatulence. NIV
should not be used if the user tends to vomit because of
the risk of aspiration. The patients are thoroughly
instructed orally and in writing to use the NIV in a
semi-sitting position (45°).
The risks of blood samples are negligible and limited
to the risk of hematoma at the site of injection.
Besides these minor risks, we believe that participation
in the present RCT is without risks.
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